They could still fight infections, but weren't running their immune systems at full throttle all the time.
Across generations, certain families have quietly carried a biological inheritance that delays the diseases most people accept as the price of growing old. Researchers at Leiden University Medical Center, studying long-lived siblings and their descendants, have identified twelve rare genetic variants — among them a striking variant in the CGAS gene — that appear to moderate the chronic inflammation quietly eroding human health over decades. Presented at the European Society of Human Genetics conference in Gothenburg, the findings suggest that the boundary between a long life and a healthy one may be written, in part, in the genome — and that reading it carefully could one day help medicine extend not merely years, but the vitality within them.
- Most people survive into old age only to spend it managing a slow accumulation of chronic disease — the gap between lifespan and healthspan has become one of medicine's most urgent unsolved problems.
- A family-based genetic study found that middle-aged children of long-lived parents developed heart and metabolic disease a full thirteen years later than their peers, signaling a heritable protection too consistent to be explained by lifestyle alone.
- Twelve rare protein-altering variants were identified across four genomic regions, with one variant in the CGAS gene — which governs the body's inflammatory alarm system — appearing independently in two separate long-lived families.
- Carriers of the CGAS variant appear to run their immune systems at a lower idle, dampening the chronic low-grade inflammation that accumulates over decades without losing the ability to fight infection — a delicate and potentially powerful balance.
- Researchers are now introducing the CGAS mutation into killifish, the shortest-lived vertebrates known, to determine whether the variant genuinely extends life in a whole organism before any consideration of human applications.
We live longer than ever before, but not always better. The slow accumulation of arthritis, heart disease, and diabetes makes old age feel like decline rather than extension — yet some families seem to escape this pattern, their members staying vigorous into extreme age. Understanding why has become one of medicine's central puzzles, and a study presented at the European Society of Human Genetics conference in Gothenburg suggests the answer lies not in individual centenarians, but in the families they come from.
Pasquale Putter and his colleagues at Leiden University Medical Center studied siblings and their descendants across generations. Their finding was striking: middle-aged children of long-lived parents developed heart and metabolic disease thirteen years later than peers whose parents had died at average ages. The protection was heritable — passed down like an inheritance. To find its genetic basis, the team analyzed the genomes of 212 groups of long-lived siblings, narrowing their search to four genomic regions and ultimately identifying twelve rare variants that altered proteins in ways potentially linked to extended healthspan.
One variant stood out above the rest. Found in the CGAS gene — which sits at the intersection of immunity and aging — it appeared in two separate long-lived families. In both cases, carriers seemed to operate with only one working copy of the gene, producing a subtler inflammatory response. They could still fight infections, but they weren't running their immune systems at full throttle constantly. That chronic, low-level inflammation that accumulates over decades appeared to be quietly dampened.
Putter was careful about what the discovery meant. The CGAS pathway is a delicate balance: suppress it entirely and you become vulnerable to infection and cancer; leave it overactive and it erodes your tissues over time. The question is whether a moderate reduction, as this variant achieves, tips the scales toward longevity without leaving people defenseless. To find out, researchers are introducing the mutation into killifish — the shortest-lived vertebrates known — at the Max Planck Institute for the Biology of Ageing in Cologne, watching whether the variant extends life and preserves health in a whole organism rather than just in laboratory cells.
The research points toward a future where aging is understood as a process shaped by specific genetic switches — identifiable and potentially influenceable. The family-based approach proved essential, separating true genetic effects from the noise of lifestyle and chance. As conference chair Alexandre Reymond observed, these findings offer the scientific community a way to focus on what matters most: not just how long people live, but how well.
We live longer than ever before, but we don't necessarily live better. People are surviving into their eighties and nineties with arthritis, heart disease, diabetes—the slow accumulation of conditions that make old age feel like a long decline rather than an extension of life. Some families, though, seem to dodge this pattern. Their members stay vigorous into extreme age, their bodies resisting the diseases that typically arrive with time. Understanding why has become one of medicine's central puzzles, and a new study presented at the European Society of Human Genetics conference in Gothenburg suggests that the answer lies not in studying individual centenarians, but in examining the families they come from.
Pasquale Putter, a doctoral researcher at Leiden University Medical Center in the Netherlands, and his colleagues took an approach that sounds simple but has proven revealing: they looked at siblings and their descendants across multiple generations. What they found was striking. Middle-aged children of long-lived parents developed heart and metabolic disease thirteen years later than their peers whose parents had died at average ages. This wasn't luck or lifestyle alone. The protection was heritable, passed down like an inheritance.
To find the genetic basis for this advantage, the team analyzed the genomes of 212 groups of long-lived siblings from the Leiden Longevity Study. Rather than searching blindly through twenty thousand genes, they first identified four genomic regions where longevity genes were likely clustered. This narrowed their focus to three hundred fifty genes—a dramatic reduction that made the next phase of analysis tractable. When they examined these regions closely, they found twelve rare genetic variants that altered proteins in ways that might influence how long and how healthily a person lives.
One variant stood out. It appeared in the CGAS gene, which sits at the intersection of immunity and aging. This gene produces a protein that detects foreign DNA inside cells—the kind that arrives with a virus or emerges when cells are damaged—and triggers an inflammatory response. The variant the researchers found appeared in two separate long-lived families, and in both cases, carriers seemed to have only one working copy of the gene instead of two. The consequence was subtle but potentially profound: their bodies mounted a weaker inflammatory response. They could still fight infections and repair damage, but they weren't running their immune systems at full throttle all the time. That constant, low-level inflammation—the kind that accumulates over decades—appeared to be dampened.
Putter described the finding with measured excitement. The magnitude of the effect in their laboratory experiments had surprised them. But he was careful about what the discovery meant. The CGAS pathway is a delicate balance. Shut it down completely and you become vulnerable to infections and cancer. Keep it overactive and chronic inflammation eats away at your tissues. The question now is whether reducing it moderately, as the variant does, tips the scales toward longevity without leaving people defenseless.
To test this, the researchers are moving to living organisms. They've chosen killifish, the shortest-lived vertebrates known, with natural lifespans of three to nine months. By introducing the CGAS mutation into killifish at the Max Planck Institute for the Biology of Ageing in Cologne, they can watch whether the variant actually extends life in a whole organism, not just in cells in a dish. They can also observe what happens to tissues and organs over time. If the killifish live longer and stay healthier, the findings will suggest that the mechanism discovered in human families might be worth pursuing further.
The research points toward a future where aging is not simply accepted as inevitable decline, but understood as a process shaped by specific genetic switches that can be identified and potentially influenced. The family-based approach proved crucial—it allowed researchers to separate true genetic effects from the noise of lifestyle, economics, and chance. As Alexandre Reymond, chair of the conference, noted, these findings give the scientific community a way to focus on the factors that matter most, and more importantly, they hint at what might extend not just lifespan, but the years of actual health that people enjoy.
Citações Notáveis
Their longer healthspan was passed down to subsequent generations— Pasquale Putter, Leiden University Medical Center
These findings allow our community to zoom in on factors tied to longevity and point to key elements to extend the healthspan of all— Professor Alexandre Reymond, conference chair
A Conversa do Hearth Outra perspectiva sobre a história
Why does studying families work better than studying individuals who happen to live a long time?
Because longevity is noisy. One person might smoke, never exercise, and live to ninety-five anyway. Another might do everything right and die at sixty. When you look at families, you're holding constant the genetic background and often the environment too—siblings grow up in the same house, share meals, inherit the same socioeconomic position. That lets you see the genetic signal more clearly.
So the CGAS gene variant reduces inflammation. Isn't inflammation sometimes necessary?
Absolutely. Inflammation is how your body fights infection and repairs damage. The problem is chronic, low-level inflammation—the kind that runs constantly in the background for decades. That's what ages you. The variant doesn't eliminate the inflammatory response; it just turns down the volume. You still mount a defense when you need to.
Why test this in killifish instead of moving straight to humans?
Because you need to know if the effect is real in a living organism before you even think about human applications. Cells in a dish behave differently than a whole body. And killifish are perfect for this—they live three to nine months, so you can watch an entire lifespan in a year. You can't do that with humans.
What happens if the killifish live longer but get sick more often?
That's the real question. Extended lifespan without extended healthspan isn't the goal. That's why they're looking at tissue health too, not just how long the fish live. If the mutation extends life but leaves them vulnerable to infections, it's not a path forward for humans.
Could this eventually become a treatment?
That's years away, if it happens at all. Right now they're just trying to understand the mechanism. But yes, if the killifish experiments confirm the effect, the long-term possibility is that you might be able to modulate CGAS activity to reduce harmful inflammation while preserving immunity. That's the dream.